Loading…
← CockpitCompetitor Analysis › INBX Inhibrx Biosciences, Inc.Open in the cockpit ↗

Inhibrx Biosciences, Inc.INBXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.

Momentum laggard 13
Mkt cap
$1.02B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$25.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.9%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$69.06
1D-6.9%
1W-23.8%
1M-27.5%
3M-30.4%
6M-37.2%
YTD-12.6%
1Y-10.7%
ATR %9.9%
Beta2.17
52w lowhigh55.5% off high

What Inhibrx Biosciences does

Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.

Has no approved product, so it earns nothing from sales and is funded by cash raised from investors. It was formed in 2024 when Sanofi bought Inhibrx's alpha-1 antitrypsin programme, and the rest of the pipeline, led by its cancer antibody candidates, was spun off as a separate listed company.

Products and services

  • INBRX-101 (alpha-1 antitrypsin deficiency)
  • Oncology biologics pipeline

Customers

  • Pulmonologists/oncologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Biologics for oncology and rare disease

What could go right

  • Pivotal trial data readouts
  • Diversified pipeline reduces single-asset risk

What could go wrong

  • Clinical trial failure risk
  • Cash runway and financing needs

Moat: none (IP / patents). Diversified biologics pipeline across multiple engineering platforms, but no approved products yet.

Headquarters: La Jolla, California, US · Founded: 2010 · Employees: 110

Named competitors

Inhibrx Biosciences at a glance

Size Inhibrx Biosciences (INBX) is a United States Health Care company (Biotechnology) with a market value of $1.02B, the 2222nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $69.06 on 18 Nov 2026.

Performance Over six months the shares fell 37.2%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 42.9% over the last twelve months (peer median +1.1%); the operating margin is -6,286.7% (peer median -18.4%).

Valuation It trades at 551.0× enterprise value to sales against a peer median of 6.2× (most expensive of 14).

Short interest Short interest is 23.0% of the free float (30 Oct 2026).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 86INBX 62
Six months, rebased to 100: Inhibrx Biosciences against the median of its 20 peers (local-currency closes).

Inhibrx Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.00M$1.30M$200,000$1.80M$2.19M
Revenue growth—+550%-89%-18%—
Gross profit-$138,000-$1.18M-$2.08M$609,000n/a
EBITDA-$124M-$133M-$329M-$218M-$128M
Net income-$142M-$140M$1.69B-$241M-$145M
Free cash flow-$133M-$130M-$197M-$198M-$116M
Capital expenditure$29,000$31,000$2.60M$4.59M$686,000
Total debt$281M$107M$8.05M$210M$207M

Quarterly statements and history in the cockpit →

Inhibrx Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%ANROSGP6882763004820020309606JBIOVOR600195688253ODTXCMPS21604587VSTMAKUMSMLYSINBX6-month return →1-month return →
Up and to the right = strong over both horizons. Inhibrx Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%0×200×400×688276300482ODTXVSTMINBXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inhibrx Biosciences is the large dot.

Inhibrx Biosciences competitors and peer comparison

Head to head with its named competitors (INBX vs GRF.MC vs VRTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Inhibrx Biosciences INBX$1.02B-37%+43%-6,287%551.0×n/a
Grifols GRF.MC$7.48B+19%+1%16%2.4×7.1%
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%

How Inhibrx Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inhibrx Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureINBXPeer medianRank in peer set
1-month return-27.5%-7.5%4th lowest of 21
6-month return-37.2%-15.1%3rd lowest of 20
Distance from 52-week high-55.5%-38.9%3rd lowest of 21
Revenue growth (TTM)+42.9%+1.1%3rd highest of 14
Operating margin-6,286.7%-18.4%lowest of 14
EV / Sales551.0×6.2×most expensive of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%

Questions

Who are Inhibrx Biosciences's main competitors?
Named competitors: Grifols (GRF.MC), Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Alto Neuroscience (ANRO), SpyGlass Pharma (SGP), Changchun BCHT Biotechnology (688276.SS), Guangzhou Wondfo Biotech (300482.SZ), Daan Gene (002030.SZ), Duality Biotherapeutics (9606.HK).
Is Inhibrx Biosciences expensive compared with its peers?
On ev / sales it trades at 551.0× against a peer median of 6.2×, most expensive of 14 in its peer set.
How has Inhibrx Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -37.2% against -15.1% for the median peer; over one year -10.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.